The atrial fibrillation paradox of heart failure

Congestive Heart Failure

Volumn 16, Issue 1, 2010, Pages 3-9

  Shelton, Rhidian J ^a   Clark, Andrew L ^a   Kaye, Gerald C ^a   Cleland, John G F ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE CLASSIFICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; VENTRICULAR DYSFUNCTION, LEFT;

EID: 74549127173     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00114.x     Document Type: Article

References (37)

1. Steinberg JS. Atrial fibrillation: an emerging epidemic? Heart 2004, 90(3):239-240.
2. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001, 22(8):623-626.
3. Khand AU, Rankin AC, Kaye GC. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000, 21(8):614-632.
4. Khand AU, Gemmell I, Rankin AC. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J 2001, 22(2):153-164.
5. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91(6A):2D-8D.
6. Mathew J, Hunsberger S, Fleg J. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000, 118(4):914-922.
7. Deedwania PC, Singh BN, Ellenbogen K. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998, 98(23):2574-2579.
8. Hampton JR, van Veldhuisen DJ, Kleber FX. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997, 349(9057):971-977.
9. Badano LP, Di Lenarda A, Bellotti P. Patients with chronic heart failure encountered in daily clinical practice are different from the " typical" patient enrolled in therapeutic trials. Ital Heart J 2003, 4(2):84-91.
10. MacIntyre K, Capewell S, Stewart S. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000, 102(10):1126-1131.
11. Wang TJ, Larson MG, Levy D. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107(23):2920-2925.
12. Vermes E, Tardif JC, Bourassa MG. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107(23):2926-2931.
13. Capewell S, MacIntyre K, Stewart S. Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet 2001, 358(9289):1213-1217.
14. Hunt SA, Abraham WT, Chin MH. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005, 112(12):1825-1852.
15. Fuster V, Ryden LE, Cannom DS. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114(7):e257-e354.
16. Saksena S, Hettrick DA, Koehler JL. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am Heart J 2007, 154(5):884-892.
17. Skanes AC, Krahn AD, Yee R. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001, 38(1):167-172.
18. Nieuwlaat R, Prins MH, Le Heuzey JY. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008, 29(9):1181-1189.
19. Khand AU, Cleland JG, Deedwania PC. Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev 2002, 7(3):267-283.
20. Swedberg K, Olsson LG, Charlesworth A. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005, 26(13):1303-1308.
21. Ducharme A, Swedberg K, Pfeffer MA. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006, 151(5):985-991.
22. Maggioni AP, Latini R, Carson PE. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149(3):548-557.
23. Kalifa J, Jalife J, Zaitsev AV. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003, 108(6):668-671.
24. Cha TJ, Ehrlich JR, Zhang L. Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure. Circulation 2004, 110(12):1520-1526.
25. Li D, Fareh S, Leung TK. Promotion of Atrial Fibrillation by Heart Failure in Dogs: Atrial Remodeling of a Different Sort. Circulation 1999, 100(1):87-95.
26. Cha YM, Redfield MM, Shen WK. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004, 109(23):2839-2843.
27. Ducharme A, Swedberg K, Pfeffer MA. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006, 152(1):86-92.
28. Nasr IA, Bouzamondo A, Hulot JS. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007, 28(4):457-462.
29. Daoud EG, Bogun F, Goyal R. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996, 94(7):1600-1606.
30. Sinno H, Derakhchan K, Libersan D. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003, 107(14):1930-1936.
31. Rivard L, Sinno H, Shiroshita-Takeshita A. The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy. Cardiovasc Res 2007, 74(1):104-113.
32. Torp-Pedersen C, Metra M, Spark P. The safety of amiodarone in patients with heart failure. J Card Fail 2007, 13(5):340-345.
33. Kober L, Torp-Pedersen C, McMurray JJ. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358(25):2678-2687.
34. Coletta AP, Cleland JG, Cullington D. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 2008, 10(9):917-920.
35. Loh E, Sutton MS, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997, 336(4):251-257.
36. Cleland JG, Findlay I, Jafri S. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004, 148(1):157-164.
37. Verheugt FW. Antithrombotic therapy in heart failure. Expert Rev Cardiovasc Ther 2006, 4(3):277-278.